- Home
- BGLC vs NLSP Comparison
BGLC vs NLSP Comparison
Compare BGLC & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- NLSP
- Stock Information
- Founded
- BGLC 2017
- NLSP 2015
- Country
- BGLC Malaysia
- NLSP Switzerland
- Employees
- BGLC N/A
- NLSP N/A
- Industry
- BGLC Medical Specialities
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- NLSP Health Care
- Exchange
- BGLC Nasdaq
- NLSP Nasdaq
- Market Cap
- BGLC 5.0M
- NLSP 12.4M
- IPO Year
- BGLC N/A
- NLSP 2021
- Fundamental
- Price
- BGLC $2.71
- NLSP $2.86
- Analyst Decision
- BGLC
- NLSP
- Analyst Count
- BGLC 0
- NLSP 0
- Target Price
- BGLC N/A
- NLSP N/A
- AVG Volume (30 Days)
- BGLC 37.4K
- NLSP 365.2K
- Earning Date
- BGLC 08-13-2025
- NLSP 07-07-2025
- Dividend Yield
- BGLC N/A
- NLSP N/A
- EPS Growth
- BGLC N/A
- NLSP N/A
- EPS
- BGLC N/A
- NLSP N/A
- Revenue
- BGLC $9,265,870.00
- NLSP N/A
- Revenue This Year
- BGLC N/A
- NLSP N/A
- Revenue Next Year
- BGLC N/A
- NLSP N/A
- P/E Ratio
- BGLC N/A
- NLSP N/A
- Revenue Growth
- BGLC N/A
- NLSP N/A
- 52 Week Low
- BGLC $2.01
- NLSP $1.30
- 52 Week High
- BGLC $8.40
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- BGLC 43.64
- NLSP 67.56
- Support Level
- BGLC $2.60
- NLSP $2.19
- Resistance Level
- BGLC $3.06
- NLSP $2.54
- Average True Range (ATR)
- BGLC 0.21
- NLSP 0.19
- MACD
- BGLC -0.06
- NLSP 0.02
- Stochastic Oscillator
- BGLC 16.27
- NLSP 82.76
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.